Clinico-pathological and molecular features associated with TP53 mutation in 3457 molecularly-profiled colorectal cancers (CRCs) | Caris Life Sciences
Portal
Order

MI Cancer Seek™ is now available for clinical ordering. Learn more.

Home / Research / Publications / Clinico-pathological and molecular features associated with TP53 mutation in 3457 molecularly-profiled colorectal cancers (CRCs)

Publications

Back

Clinico-pathological and molecular features associated with TP53 mutation in 3457 molecularly-profiled colorectal cancers (CRCs)

– Caris Life Sciences

Poster

Background

Deregulation of the p53 tumor suppressor gene (TP53) is a key event contributing to transformation and aggressive metastatic features of CRC. Patients with TP53 mutation are often resistant to therapy and carry a poor prognosis.

Download Publication

Discover
More

  • Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy

    – Caris Life Sciences

    Manuscript

    Highlights: 1. GEA tumors with mutations in KRAS, TP53 and RAS-MAPK pathway are associated with high PD-L1 CPS in the pMMR&MSS subgroup. 2. RAS-MAPK pathway alteration may… […]

  • Correlation of tumor mutational burden (TMB) with CDKN2A and TP53 mutations

    – Caris Life Sciences

    Poster

    Conclusions: Mutation of TP53 and/or CDKN2A is associated with increased mean TMB relative to WT. • Mean TMB was highest for tumors bearing damaging mutations… […]
Learn More

Ready to Get Started on the Journey?

Name(Required)